公开(公告)号：EP1090908A3

公开(公告)日：2001-05-16

申请号：EP00124275.9

申请日：1996-04-18

Applicant: ABBOTT LABORATORIES

Inventor： Arendsen, David L. ,  Baker, William R. ,  Fakhoury, Stephen A. ,  Fung, K.L. Anthony ,  Garvey, David S. ,  McClellan, William J. ,  O'Connor, Stephen J. ,  Prasad, Rajnandan N. ,  Rockway, Todd W. ,  Rosenberg, Saul H. ,  Stein, Herman H. ,  Shen, Wang ,  Stout, David M. ,  Sullivan, Gerard M. ,  Augeri, David J.

IPC: C07C233/60 ,  C07D333/20 ,  C07C233/58 ,  C07C233/59 ,  C07C235/40 ,  A61K31/19 ,  A61K31/215 ,  A61K31/38 ,  A61K31/16

CPC classification number: C07C235/82 ,  C07C233/58 ,  C07C233/59 ,  C07C233/60 ,  C07C235/40 ,  C07C2601/04 ,  C07D333/20

Abstract: The present invention provides a compound of formula (II) or a pharmaceutically acceptable salt thereof, which is useful for inhibiting protein farnesyltransferase and the farnesylation of the oncogene protein Ras, processes for the preparation of the compounds of the invention in addition to intermediates useful in these processes, a pharmaceutical composition, and to methods of using such compounds.

Abstract translation: 本发明提供式（II）化合物或其药学上可接受的盐，其可用于抑制蛋白质法呢基转移酶和癌基因蛋白Ras的法呢基化，制备本发明化合物的方法除了可用于 这些方法，药物组合物，以及使用这些化合物的方法。

公开(公告)号：EP1090908A2

公开(公告)日：2001-04-11

申请号：EP00124275.9

申请日：1996-04-18

Applicant: ABBOTT LABORATORIES

Inventor： Arendsen, David L. ,  Baker, William R. ,  Fakhoury, Stephen A. ,  Fung, K.L. Anthony ,  Garvey, David S. ,  McClellan, William J. ,  O'Connor, Stephen J. ,  Prasad, Rajnandan N. ,  Rockway, Todd W. ,  Rosenberg, Saul H. ,  Stein, Herman H. ,  Shen, Wang ,  Stout, David M. ,  Sullivan, Gerard M. ,  Augeri, David J.

IPC: C07C233/60 ,  C07D333/20 ,  C07C233/58 ,  C07C233/59 ,  C07C235/40 ,  A61K31/19 ,  A61K31/215 ,  A61K31/38 ,  A61K31/16

CPC classification number: C07C235/82 ,  C07C233/58 ,  C07C233/59 ,  C07C233/60 ,  C07C235/40 ,  C07C2601/04 ,  C07D333/20

Abstract: The present invention provides a compound of formula (II) or a pharmaceutically acceptable salt thereof, which is useful for inhibiting protein farnesyltransferase and the farnesylation of the oncogene protein Ras, processes for the preparation of the compounds of the invention in addition to intermediates useful in these processes, a pharmaceutical composition, and to methods of using such compounds.

Abstract translation: 本发明提供了用于抑制蛋白质法尼基转移酶和癌基因蛋白Ras的法尼基化的式（II）化合物或其药学上可接受的盐，除用于制备本发明化合物的中间体 这些方法，药物组合物，以及使用这些化合物的方法。

公开(公告)号：EP0405506A1

公开(公告)日：1991-01-02

申请号：EP90112261.4

申请日：1990-06-27

Applicant: ABBOTT LABORATORIES

Inventor： Chung, John Y.-L. ,  Tufano, Michael D. ,  May, Paul D. ,  Shiosaki, Kazumi ,  Nadzan, Alex M. ,  Garvey, David S. ,  Shue, Youe-Kong ,  Brodie, Mark S. ,  Holladay, Mark W.

IPC: C07K5/00 ,  A61K37/02

CPC classification number: C07K5/1016 ,  A61K38/00 ,  C07K5/0207 ,  C07K5/0808 ,  C07K5/1024

Abstract: A tetrapeptide type-B CCK receptor ligand of the formula
A-B-C-D
or a pharmaceutically acceptable salt thereof, which is useful for treating central nervous system disorders, substance abuse, gastrointestinal disorders, endocrine disorders, eating-related disorders and treatment of shock, respiratory and cardiocirculatory insufficiencies.

Abstract translation: 用于治疗中枢神经系统疾病，药物滥用，胃肠道疾病，内分泌紊乱，进食相关疾病和休克，呼吸和心脏循环治疗的ABCD的四肽B型CCK受体配体或其药学上可接受的盐 不足。